| Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective … DJ Pinato, J Tabernero, M Bower, L Scotti, M Patel, E Colomba, S Dolly, ... The Lancet Oncology 22 (12), 1669-1680, 2021 | 115 | 2021 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 98 | 2021 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 77 | 2020 |
| High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients L Cantini, F Pecci, DP Hurkmans, RA Belderbos, A Lanese, C Copparoni, ... European journal of cancer 144, 41-48, 2021 | 75 | 2021 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 70 | 2020 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 62 | 2020 |
| Emerging treatments for malignant pleural mesothelioma: where are we heading? L Cantini, R Hassan, DH Sterman, JGJV Aerts Frontiers in Oncology 10, 343, 2020 | 60 | 2020 |
| Outcomes of the SARS-CoV-2 omicron (B. 1.1. 529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre … DJ Pinato, D Ferrante, G Hanbury, M Bower, R Salazar, O Mirallas, ... The Lancet Oncology 23 (7), 865-875, 2022 | 56 | 2022 |
| Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world … L Cantini, G Mentrasti, GL Russo, D Signorelli, G Pasello, E Rijavec, ... ESMO open 7 (2), 100406, 2022 | 49 | 2022 |
| The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1≥ 50% advanced non-small-cell lung cancer GL Banna, A Cortellini, DL Cortinovis, M Tiseo, J Aerts, F Barbieri, ... Esmo Open 6 (2), 100078, 2021 | 47 | 2021 |
| Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study A Cortellini, A De Giglio, K Cannita, DL Cortinovis, R Cornelissen, ... Thoracic Cancer 12 (6), 880-889, 2021 | 40 | 2021 |
| The gustave roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line … E Lenci, L Cantini, F Pecci, V Cognigni, V Agostinelli, G Mentrasti, A Lupi, ... Journal of Clinical Medicine 10 (5), 1005, 2021 | 30 | 2021 |
| Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer A Bittoni, F Pecci, G Mentrasti, S Crocetti, A Lupi, A Lanese, C Pellei, ... Annals of Translational Medicine 9 (3), 2021 | 30 | 2021 |
| Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy S Buti, M Bersanelli, F Perrone, S Bracarda, M Di Maio, R Giusti, O Nigro, ... European Journal of Cancer 150, 224-231, 2021 | 27 | 2021 |
| Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program L Cantini, RA Belderbos, CJ Gooijer, DW Dumoulin, R Cornelissen, ... Translational Lung Cancer Research 9 (4), 1169, 2020 | 27 | 2020 |
| Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis L Cantini, F Merloni, S Rinaldi, E Lenci, G Marcantognini, T Meletani, ... Critical reviews in oncology/hematology 151, 102974, 2020 | 26 | 2020 |
| Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer DJ Pinato, D Ferrante, J Aguilar-Company, M Bower, R Salazar, ... European Journal of Cancer 171, 64-74, 2022 | 23 | 2022 |
| Beyond microsatellite instability: evolving strategies integrating immunotherapy for microsatellite stable colorectal cancer F Pecci, L Cantini, A Bittoni, E Lenci, A Lupi, S Crocetti, E Giglio, ... Current Treatment Options in Oncology 22 (8), 69, 2021 | 21 | 2021 |
| Optimal management of resected gastric cancer R Giampieri, M Del Prete, L Cantini, MG Baleani, A Bittoni, E Maccaroni, ... Cancer Management and Research, 1605-1618, 2018 | 21 | 2018 |
| Scientia potentia est: how the Italian world of oncology changes in the COVID-19 pandemic Z Ballatore, L Bastianelli, F Merloni, N Ranallo, L Cantini, ... JCO Global Oncology 6, 1017-1023, 2020 | 20 | 2020 |
